Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial

European Radiology

Volumn 19, Issue 11, 2009, Pages 2728-2738

  Koh, Dow Mu ^a,d   Blackledge, Matthew ^a,d   Collins, David J ^a,d   Padhani, Anwar R ^b   Wallace, Toni ^a   Wilton, Benjamin ^d   Taylor, N Jane ^b   Stirling, J James ^b   Sinha, Rajesh ^a   Walicke, Pat ^c   Leach, Martin O ^d   Judson, Ian ^a   Nathan, Paul ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

^c OXiGENE Inc   (United States)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Diffusion weighted MR; Reproducibility; Response assessment; Tumour

Indexed keywords

BEVACIZUMAB; COMBRETASTATIN A4 PHOSPHATE;

ADULT; AGED; ANGIOSARCOMA; ARTICLE; BREAST CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DOSE RESPONSE; DRUG DOSE ESCALATION; ECHO PLANAR IMAGING; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; MELANOMA; NEUROENDOCRINE TUMOR; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; REPRODUCIBILITY; SARCOMA; SOLID TUMOR; TUMOR VOLUME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIFFUSION MAGNETIC RESONANCE IMAGING; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASMS; PHANTOMS, IMAGING; REPRODUCIBILITY OF RESULTS; STILBENES; TIME FACTORS;

EID: 70350172813     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-009-1469-4     Document Type: Article

References (29)

1. Koh DM, Collins DJ (2007) Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 188:1622-1635
2. Kamel IR, Bluemke DA, Ramsey D et al (2003) Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol 181:708-710
3. Mardor Y, Pfeffer R, Spiegelmann R et al (2003) Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol 21:1094-1100
4. Hein PA, Kremser C, Judmaier W et al (2003) Diffusion-weighted magnetic resonance imaging for monitoring diffusion changes in rectal carcinoma during combined, preoperative chemoradiation: Preliminary results of a prospective study. Eur J Radiol 45:214-222
5. Byun WM, Shin SO, Chang Y et al (2002) Diffusion-weighted MR imaging of metastatic disease of the spine: Assessment of response to therapy. AJNR Am J Neuroradiol 23:906-912
6. Geschwind JF, Artemov D, Abraham S et al (2000) Chemoembolization of liver tumor in a rabbit model: Assessment of tumor cell death with diffusion-weighted MR imaging and histologic analysis. J Vasc Interv Radiol 11:1245-1255
7. Koh DM, Scurr E, Collins D et al (2007) Predicting response of colorectal hepatic metastasis: Value of pretreatment apparent diffusion coefficients. AJR Am J Roentgenol 188:1001-1008
8. Kwee TC, Takahara T, Koh DM et al (2008) Comparison and reproducibility of ADC measurements in breathhold, respiratory triggered, and free-breathing diffusion-weighted MR imaging of the liver. J Magn Reson Imaging 28:1141-1148
9. Thoeny HC, De Keyzer F, Chen F et al (2005) Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin A-4 phosphate after repeated administration. Neoplasia 7:779-787
10. Thoeny HC, De Keyzer F, Vandecaveye V et al (2005) Effect of vascular targeting agent in rat tumor model: Dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology 237:492-499
11. Dowlati A, Robertson K, Cooney M et al (2002) A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62:3408-3416
12. Galbraith SM, Maxwell RJ, Lodge MA et al (2003) Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21:2831-2842
13. Stevenson JP, Rosen M, Sun W et al (2003) Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21:4428-4438
14. Ellis LM (2005) Bevacizumab. Nat Rev Drug Discov Suppl:S8-9
15. Jain RK (2005) Antiangiogenic therapy for cancer: Current and emerging concepts. Oncology (Williston Park) 19:7-16
16. Hormigo A, Gutin PH, Rafii S (2007) Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers. Cancer Cell 11:6-8
17. Batchelor TT, Sorensen AG, di Tomaso E et al (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95
18. Delakis I, Moore EM, Leach MO et al (2004) Developing a quality control protocol for diffusion imaging on a clinical MRI system. Phys Med Biol 49:1409-1422
19. Bland JM, Altman DG (1999) Measuring agreement in method comparison studies. Stat Methods Med Res 8:135-160
20. Galbraith SM, Lodge MA, Taylor NJ et al (2002) Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: Comparison of quantitative and semi-quantitative analysis. NMR Biomed 15:132-142
21. Thoeny HC, De Keyzer F, Chen F et al (2005) Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology 234:756-764
22. Malcontenti-Wilson C, Muralidharan V, Skinner S et al (2001) Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model. Clin Cancer Res 7:1052-1060
23. Tozer GM, Prise VE, Wilson J et al (2001) Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 61:6413-6422
24. Tozer GM, Akerman S, Cross NA et al (2008) Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors. Cancer Res 68:2301-2311
25. Cui Y, Zhang XP, Sun YS et al (2008) Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 248:894-900
26. Dzik-Jurasz A, Domenig C, George M et al (2002) Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 360:307-308
27. DeVries AF, Kremser C, Hein PA et al (2003) Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys 56:958-965
28. Hamstra DA, Galban CJ, Meyer CR et al (2008) Functional diffusion map as an early imaging biomarker for high-grade glioma: Correlation with conventional radiologic response and overall survival. J Clin Oncol 26:3387-3394
29. Lee KC, Bradley DA, Hussain M et al (2007) A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia 9:1003-1011